BioLife Solutions, Inc. (NASDAQ:BLFS) Shares Acquired by Cerity Partners LLC

Cerity Partners LLC grew its stake in BioLife Solutions, Inc. (NASDAQ:BLFS) by 6.6% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 44,914 shares of the medical equipment provider’s stock after buying an additional 2,776 shares during the quarter. Cerity Partners LLC’s holdings in BioLife Solutions were worth $1,125,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. 1620 Investment Advisors Inc. purchased a new position in shares of BioLife Solutions in the 2nd quarter valued at about $35,000. Isthmus Partners LLC increased its stake in shares of BioLife Solutions by 34.4% in the 2nd quarter. Isthmus Partners LLC now owns 165,247 shares of the medical equipment provider’s stock valued at $35,000 after purchasing an additional 42,265 shares in the last quarter. Quest Partners LLC purchased a new position in shares of BioLife Solutions in the 3rd quarter valued at about $57,000. GAMMA Investing LLC increased its stake in shares of BioLife Solutions by 29.4% in the 3rd quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock valued at $83,000 after purchasing an additional 748 shares in the last quarter. Finally, Canada Pension Plan Investment Board purchased a new position in shares of BioLife Solutions in the 2nd quarter valued at about $122,000. Hedge funds and other institutional investors own 93.24% of the company’s stock.

Insider Activity

In other news, CRO Garrie Richardson sold 3,070 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $25.12, for a total value of $77,118.40. Following the completion of the sale, the executive now directly owns 114,773 shares in the company, valued at $2,883,097.76. This represents a 2.61 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Aby J. Mathew sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $23.28, for a total value of $232,800.00. Following the completion of the transaction, the executive vice president now owns 317,716 shares in the company, valued at $7,396,428.48. This represents a 3.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 71,313 shares of company stock worth $1,572,899 over the last ninety days. Corporate insiders own 2.20% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have commented on the company. Northland Securities boosted their price objective on BioLife Solutions from $26.00 to $28.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. Craig Hallum boosted their price objective on BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. HC Wainwright cut their price objective on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating for the company in a research note on Monday, November 18th. Finally, TD Cowen boosted their price objective on BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. According to MarketBeat.com, BioLife Solutions currently has a consensus rating of “Moderate Buy” and a consensus price target of $27.50.

BioLife Solutions Price Performance

BLFS stock opened at $26.38 on Thursday. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78. The business has a 50 day simple moving average of $24.36 and a 200-day simple moving average of $23.34. The firm has a market capitalization of $1.22 billion, a PE ratio of -24.89 and a beta of 1.91. BioLife Solutions, Inc. has a 1 year low of $12.45 and a 1 year high of $28.88.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.